Eli Lilly has announced a collaboration with technology company NVIDIA to develop the pharmaceutical industry's most powerful supercomputer, utilising over 1,000 B300 graphics processing units (GPUs) to support end-to-end AI lifecycle from data ingestion to high-throughput inference. The AI factory infrastructure will accelerate drug discovery through machine learning models, trained on millions of experimental data points with proprietary algorithms for biopharmaceutical ecosystem collaboration. Lilly chief information and digital officer Diogo Rau highlighted 150 years of historical data as a strategic asset enabling new scientific standards through targeted AI model deployment across discovery and development workflows.

The supercomputer will enable rapid iteration cycles with scientific AI agents supporting reasoning and planning in digital and physical environments, including advanced medical imaging for disease progression monitoring and biomarker identification. Manufacturing applications include digital twin technology and NVIDIA robotics integration, improving production efficiency and reducing downtime.

According to PharmCube's NextBiopharm® database, this is not NVIDIA's first collaboration with the pharma industry, as it previously entered an agreement with Genesis Therapeutics for an undisclosed amount. Click here to request a free trial for NextBiopharm®.